Skip to main content
Back
Watch Compare

Spero Therapeutics, Inc.

Data quality: 100%
SPRO
Nasdaq Manufacturing Chemicals
$2.67
▼ $0.11 (-3.96%)
Mkt Cap: 161.52 M
Price
$2.79
Mkt Cap
161.52 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue grew 38.31% annually over 5 years — strong growth
ROE of 28.90% indicates high profitability
Negative free cash flow of -12.62 M

Growth

Revenue Growth (5Y)
38.31%
Above sector avg (1.82%)
Revenue (1Y)39.24%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
28.90%
Above sector avg (-53.53%)
ROIC13.97%
Net Margin12.83%
Op. Margin9.45%

Safety

Debt / Equity
N/A
Current Ratio3.83
Interest CoverageN/A

Valuation

PE (TTM|2027)
18.84 | 3.67
Above sector avg (-1.48)
P/B Ratio6.10
EV/EBITDA17.88
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1366 peers)
Metric Stock Sector Median
P/E 18.8 -1.5
P/B 6.1 1.6
ROE % 28.9 -53.5
Net Margin % 12.8 -41.5
Rev Growth 5Y % 38.3 1.8
D/E — 0.3

Analyst Price Target

1 analyst
Hold
Current
$2.67
+49.8%
Target
$4.00
$4.00
$4.00
$4.00
Forecast
Forward P/E 3.51
Forward EPS $0.76
EPS Growth (est.) +13.4%
Est. Revenue 0.0

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 $0.76
$0.76 – $0.76
 0.0 1
FY2026 $0.67
$0.67 – $0.67
 0.0 1

Earnings Surprises

Last 3 quarters
Quarter Est. EPS Actual EPS Surprise
Q32025 -$0.25 -$0.13 +48.0%
Q22025 -$0.38 -$0.03 +92.1%
Q12025 -$0.44 -$0.25 +43.8%

ETFs Holding This Stock

BRSIX BRSIX
0.08% weight
BOSVX BOSVX
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 39.24% Revenue Growth (3Y) -19.77%
Earnings Growth (1Y) N/A Earnings Growth (3Y) -38.69%
Revenue Growth (5Y) 38.31% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 66.80 M Net Income (TTM) 8.57 M
ROE 28.90% ROA 14.74%
Gross Margin N/A Operating Margin 9.45%
Net Margin 12.83% Free Cash Flow (TTM) -12.62 M
ROIC 13.97% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3.83
Interest Coverage N/A Asset Turnover 1.15
Working Capital 38.67 M Tangible Book Value 26.49 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 18.84 Forward P/E N/A
P/B Ratio 6.10 P/S Ratio 2.42
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 17.88 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -7.82%
Market Cap 161.52 M Enterprise Value 112.90 M
Per Share
EPS (Diluted TTM) 0.15 Revenue / Share 1.15
FCF / Share -0.22 OCF / Share -0.22
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion -147.27%
SBC-Adj. FCF -18.10 M Growth Momentum 0.93

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 66.80 M 47.98 M 103.78 M 53.51 M 18.26 M
Net Income 8.57 M -68.57 M 22.81 M -46.42 M -89.80 M
EPS (Diluted) 0.15 -1.27 0.43 -1.23 —
Gross Profit — — — — —
Operating Income 6.31 M -73.36 M 21.48 M -42.20 M -87.97 M
EBITDA — — — — —
R&D Expenses 38.47 M 96.76 M 51.44 M 47.59 M 64.53 M
SG&A Expenses — — — — —
D&A 0.0 2,000.0 367,000.0 869,000.0 646,000.0
Interest Expense — — — — —
Income Tax 261,000.0 0.0 2.60 M 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 68.92 M 110.54 M 182.39 M 124.80 M 171.07 M
Total Liabilities 9.90 M 64.42 M 75.50 M 48.87 M 82.78 M
Shareholders' Equity 59.02 M 46.12 M 106.89 M 75.93 M 88.29 M
Total Debt — — — — —
Cash & Equivalents 40.27 M 52.89 M 76.33 M 109.11 M 112.58 M
Current Assets 67.29 M 107.28 M 131.21 M 113.57 M 157.87 M
Current Liabilities 8.87 M 49.07 M 37.15 M 21.65 M 18.67 M